However, a first clinical trial for repurposing the histamine H1 receptor antagonist fexofenadine demonstrated the efficacy of the drug in reducing the ACR in patients with Type 2 diabetes mellitus (at least from six months) and stage 2 or 3 diabetic nephropathy. Here, HRH1 is linked to type 2 diabetes mellitus.